Related Experiment Video

Updated: Aug 19, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Current status of antitumor therapy with monoclonal antibodies

D A Scheinberg1, A N Houghton

  • 1Memorial Sloan-Kettering Cancer Center.

Oncology (Williston Park, N.Y.)
|May 1, 1987
PubMed

Insights

Monoclonal antibodies offer targeted cancer therapy by recognizing specific antigens. However, realizing their full therapeutic potential requires overcoming challenges identified in clinical trials.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Monoclonal antibodies (mAbs) are engineered proteins that can precisely target specific molecules or cells.
  • Their ability to bind to unique antigenic determinants presents significant opportunities for therapeutic interventions, particularly in cancer treatment.

Purpose of the Study:

  • To evaluate the extent to which the therapeutic potential of monoclonal antibodies has been realized in clinical practice.
  • To identify and analyze the challenges and problems encountered during clinical trials of monoclonal antibodies for cancer therapy.

Main Methods:

  • Review of existing clinical trial data and literature on monoclonal antibody therapies for cancer.
  • Analysis of reported efficacy, safety profiles, and treatment outcomes.

Main Results:

  • Monoclonal antibodies have shown promise in specific cancer types, demonstrating targeted therapeutic effects.
  • Clinical trials have revealed challenges including antigen heterogeneity, resistance mechanisms, and immune-related adverse events.

Conclusions:

  • While monoclonal antibodies represent a powerful tool in oncology, their clinical application is complex.
  • Further research and development are needed to optimize efficacy and mitigate adverse events for broader successful application in cancer therapy.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.